We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Blood Test Accurately Detects Idiopathic Pulmonary Fibrosis

By LabMedica International staff writers
Posted on 23 Mar 2016
Print article
Image: Histopathology of the architecture of the lung in idiopathic pulmonary fibrosis (IPF) is characterized by a so-called “honeycomb” pattern with airways separated by bands of inflamed fibrous connective tissue and to a lesser extent, smooth muscle (Photo courtesy of Dr. Robert Dunstan).
Image: Histopathology of the architecture of the lung in idiopathic pulmonary fibrosis (IPF) is characterized by a so-called “honeycomb” pattern with airways separated by bands of inflamed fibrous connective tissue and to a lesser extent, smooth muscle (Photo courtesy of Dr. Robert Dunstan).
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive and lethal lung disease characterized by scarring and reduction in the lungs' capacity to absorb oxygen. In the USA, around 100,000 people are currently affected by IPF, with approximately 30,000 to 40,000 new cases diagnosed each year.

Diagnosis of IPF is based on a range of clinical, laboratory, radiological and pathological tests, often to exclude other conditions first. The key diagnostic test currently available is High Resolution Computed Tomography (HRCT), a costly procedure to which access is limited in many countries. The disease has a poor prognosis, with many patients surviving only three to five years after diagnosis.

Scientists at the Liège University Hospital (Belgium) carried out a clinical study of 78 subjects, 21 were non-treated patients with IPF, 27 patients had been treated for IPF, and 30 were healthy volunteers. Analysis of the preliminary data revealed that a single NuQ biomarker assay (VolitionRx; Namur, Belgium) detected 86% of the non-treated IPF patients (18 of 21) from the healthy subjects with only 6 false positives (80% specificity). Julien Guiot, MD, project coordinator from Liège University Hospital, said, “At present, relatively little is known about this deadly disease. An accurate, cost-effective diagnostic for IPF could have a significant impact in assisting doctors in their efforts to understand the disease and develop a more viable treatment and potential cure.”

Jake Micallef, PhD, MBA, Chief Scientific Officer at VolitionRx, said, “Some NuQ biomarker assays are particularly appropriate for the detection of inflammatory diseases such as IPF. To have achieved such impressive accuracy for detecting IPF using only a single such NuQ biomarker assay in this pilot study is very encouraging. Our next step will be to work on a larger study sample and to include additional NuQ biomarker assays to form a panel blood test that could have even greater accuracy.”

Related Links:

Liège University Hospital 
VolitionRx 


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.